Ensysce BiosciencesENSC
13F holders, Q2 2025 (June 30)11holders +2
4new positions
2sold out
$2.23avg. 13F price*
At the end of Q2 2025, 11 institutions reported holding Ensysce Biosciences Inc. (ENSC) in their 13F filings, up 2 from Q1 2025. 4 opened new positions and 2 sold out. The largest holders were Perceptive Advisors LLC ($193K), Adage Capital Partners Gp, L.L.C. ($167K) and Geode Capital Management, LLC ($23K).
- Company
- Ensysce Biosciences Inc.
- CUSIP
- 293602504
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $29K |
| Exits | 2 | $479K |
All 13F filers, Q1 2025 → Q2 2025: 13,908 shares bought and 187,908 shares sold, net −174,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Perceptive Advisors LLC | 0.01% | No change | 86,666 | $193K |
| Adage Capital Partners Gp, L.L.C. | 0.00% | No change | 74,711 | $167K |
| Geode Capital Management, LLC | 0.00% | New | 10,161 | $23K |
| FNY Investment Advisers, LLC | 0.00% | No change | 3,000 | $6K |
| SBI Securities Co., Ltd. | 0.00% | New | 2,336 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +210.4% | 1,369 | $3K |
| Morgan Stanley | 0.00% | New | 378 | $843 |
| UBS Group AG | 0.00% | Reduce -72.9% | 354 | $789 |
| Raymond James Financial Inc. | 0.00% | New | 94 | $210 |
| BlackRock, Inc. | 0.00% | No change | 65 | $145 |
| Bank of America Corp. | 0.00% | Add +137.5% | 19 | $42 |
"% of holder's portfolio" is ENSC's weight in each manager's 13F, not the share of Ensysce Biosciences Inc. the manager owns.